Design, validation, and development of novel peptidomimetic therapeutics targeting SARS-CoV-2 replication
Implementing Organization
International Centre for Genetic Engineering and Biotechnology (ICGEB)
Principal Investigator
Dr Arockiasamy Arulandu
Group Leader
|
International Centre for Genetic Engineering and Biotechnology (ICGEB)
About
The aim of this study is to deliver novel peptidomimetic inhibitors targeting Mpro and PLpro with therapeutic potential, validated in vitro and in vivo using recent animal models for SARS-CoV-2.
Disclaimer:
Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.
Please enter your details
Please provide your name and email to continue. Your details are saved in this browser for future use.
Latest Updates
Loading…
⚠️
You are leaving this website
You are about to be redirected to an external website that is not operated by
India Science, Technology & Innovation (ISTI) Portal.